3rd Quarter - Report

AKIN GUMP STRAUSS HAUER & FELD for SHATTERPROOF

Period 3rd Quarter 2022 Filed Oct 20, 2022 Signed by Brian Pomper

Official filing
Firm
AKIN GUMP STRAUSS HAUER & FELD
Client
SHATTERPROOF
Income
$30,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.

LobbyistCovered position, as disclosed
LOUIS AGNELLO —
JULIE NOLAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6311 (117th), H.R. 2067 (117th), S. 285 (117th), S. 445 (117th), H.R. 5218 (117th), S. 2235 (117th), H.R. 2364 (117th), H.R. 955 (117th), H.R. 1384 (117th), S. 3418 (117th), S. 1160 (117th), H.R. 2538 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.